Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 11129 - 11136 of 11616 results
Section 1(b) Intent-To-Use Applications: Evidence of Bona Fide Intent Required
November 15, 2011| Blog| Viewpoint
Psychiatric Disabilities Under the ADA: proposed changes to diagnostic tool may result in a broader definition of "disability"
November 14, 2011| Blog| Viewpoint
Arbitrator, Not Court, Should Determine Whether Employment Agreements Permit Collective Arbitration, Says New York Appellate Court
November 10, 2011| Blog| Viewpoint
Breaking News -- Wall Street Journal: Facebook Close to Settlement with the Federal Trade Commission
November 10, 2011| Blog| Viewpoint
HHS OCR Begins HIPAA Audits
November 9, 2011| Blog| Viewpoint
Recent Developments Regarding Issuer Responsibility for Reviewing Initial Offering Prices of Bonds
November 9, 2011| Blog| Viewpoint
Delay in Publication of Sunshine Act Regulations Persists Despite Bipartisan Pressure
November 8, 2011| Blog| Viewpoint
Senators Kerry & McCain to FTC and Commerce: Get Moving on Final Reports
November 8, 2011| Blog| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.